Ostarine vs ligandrol: what the trials actually compare

Every forum thread on this pair ends in a confident verdict: one is stronger, one is safer, one is “not anabolic enough” to be worth the suppression. None of those verdicts comes from a study, because no study has ever put the two compounds in the same group of people. What exists is one good trial of each, in different populations, asking different questions, and a handful of systematic reviews that pool them with everything else in the class.

This is what the published work actually compares.

What a head-to-head would have to look like

One randomised trial, one population, both compounds, one set of measurements. Search PubMed for records mentioning both compounds and you get a handful of hits: reviews, an analytical method paper, a pharmacology review, and a sports-medicine systematic review. Not one of them is a trial where participants were randomised to receive both.

The closest thing to a direct comparison is a 2020 experiment in ovariectomised rats, where the two compounds were given to different groups of the same model and compared against untreated controls. Twelve to fifteen animals per group, five weeks of treatment, and a read-out on muscle capillary density, fibre size, enzyme activity and intramuscular fat. Both compounds improved capillary density, fibre size did not change under either, and at the highest level both showed an effect the authors flag as unfavourable, with more muscle weight and intramuscular fat after ligandrol. It is a decent mechanistic paper. It is not a comparison of how the two behave in people, and it should not be described as one.

Ligandrol: 76 young men, 21 days

The 2013 paper from Basaria’s group is the most-cited ligandrol study and the design explains the usual misreadings. Seventy-six healthy men aged 21 to 50 were randomised to placebo or to one of three ascending exposure levels of LGD-4033, taken daily for 21 days. Blood was drawn during treatment and for five weeks after, and the read-outs were broad: blood counts, chemistries, lipids, prostate-specific antigen, ECG, hormones, lean and fat mass by DXA, and muscle strength.

What it found, in the paper’s own framing:

• No drug-related serious adverse events, and the frequency of adverse events was similar between active and placebo groups.
• Haemoglobin, PSA, liver transaminases and QT intervals did not change significantly at any level.
• A long elimination half-life, with accumulation on repeat administration proportional to the level given.
• Suppression of total testosterone, sex hormone-binding globulin, HDL cholesterol and triglycerides that tracked the level given.
• Follicle-stimulating hormone and free testosterone suppressed at the top level only.
• Lean body mass rose as the level given rose. Fat mass did not change significantly.
• Hormone levels and lipids returned to baseline after treatment stopped.

The two facts people leave out are the duration and the recovery. What happens after stopping is its own thin literature, and thinner than the forums assume: clomiphene has a thin placebo-controlled literature of its own, in men, off-label, for an indication it was never approved for. Twenty-one days is a pharmacokinetic and safety study with a body-composition signal attached, not a results period. And the hormonal findings are the more interesting result in the paper than the lean mass is, because a compound that suppresses endogenous testosterone, its binding globulin and HDL in a way that tracks the level given, and then lets them return to baseline on stopping, is a compound whose whole profile is tied to the length of the exposure.

Ostarine: 120 older adults, 12 weeks

The 2011 phase II trial of GTx-024, better known as enobosarm or MK-2866, was a different study in a different place. Twelve weeks, double-blind, placebo-controlled, in 120 healthy elderly men over 60 and postmenopausal women. The primary endpoint was total lean body mass by DXA; secondary endpoints included physical function, body weight, insulin resistance and safety.

The headline results: increases in total lean body mass that tracked the level given and were statistically significant, improvements in physical function, an improvement in insulin resistance, and an incidence of adverse events similar between groups. The authors concluded it was well tolerated and worth pursuing in muscle-wasting conditions.

Two details matter for anyone comparing the two compounds. First, the population: people in their sixties and beyond, where the problem being treated is age-related loss of muscle, not the short-term goal of a healthy 25-year-old. Second, the twelve weeks are three times longer than the ligandrol trial, so the lean-mass gains the two papers report are not measured over a comparable window, and nobody has ever shown what happens when you extend either to a year.

What happens when you pool them

This is where the reviews get interesting, because pooling is the only way anyone has ever compared these compounds in numbers at the same time.

A 2025 systematic review in Clinical Endocrinology pulled nine randomised controlled trials, 970 patients, mean age 57.1 years with a range from 35.3 to 75.9, and a mean follow-up of 80 days with a range from 14 to 180. Six different SARMs were analysed, LGD-4033 and GTx-024 among them. Here are the pooled means before and after intervention:

Look at that table for a second, because it is the most honest summary of this whole literature. Across 970 patients and every SARM ever put through a randomised trial, pooled lean body mass moved by about a kilogram and a half. Fat mass did not move. And of the three performance measures the review pooled, stair-climbing power went the wrong way while one-repetition leg press went up — 352 W to 315 W against 1,823 N to 2,191 N, roughly 10 % down against 20 % up. A single pooled direction is not a claim about any compound; it is a reminder that the pool mixes doses, populations and endpoints. The review’s own conclusion is that SARMs have a positive effect on physical performance and body composition with moderate rates of mild to moderate adverse events and a low rate of severe ones, which is a defensible summary of a heterogeneous pool, not a promise about any individual compound at any individual exposure.

The compound-level granularity simply is not there. Neither SARM’s own paper isolates its effect in a way that this kind of pooling can preserve.

The part the trials do not cover

The trial populations are not the population most people picture when they picture a SARM, and that gap is worth stating plainly rather than glossing over.

A 2025 systematic review in the American Journal of Sports Medicine took 72 articles published between 2003 and 2022 and did two things. It estimated that SARM use among athletes runs at one to three percent. And it catalogued the case reports: 13 reports describing 15 cases, all men, median age 32 with a range of 19 to 52, more than half identified as athletes, all of them taking the compounds orally, with a mean course of eight weeks. The reported problems included drug-induced liver injury, myocarditis and tendon rupture, alongside the bone remodelling, testosterone suppression and prostate enlargement that the trials themselves documented. The review states plainly that the compounds have no Food and Drug Administration approved use, that athletes report consuming them at much higher exposures than were clinically studied, and that most of these compounds have been shown to be contaminated with other substances.

The two findings that deserve the most weight are the last two. A compound tested for weeks in a trial population is not the compound on a shelf for eight weeks at a self-selected exposure, and a product that arrives in an unmarked bag has a composition problem that a clinical trial design cannot fix.

That last point is not a theoretical worry. A five-year market surveillance study by the General European Official Medicines Control Laboratories network collected 324 samples and 354 results across 13 countries, and the five most frequently reported molecules in seized product were ibutamoren, ligandrol, ostarine, cardarine and andarine. Sixty-five percent of the seized products were presented as medicines and 24 percent as dietary supplements, which means the buyer frequently does not know they are taking an unapproved pharmaceutical. From the limited quantitative data the authors could assume most samples contain active quantities and some are even overdosed.

This matters for the comparison question more than anything else in the literature. When two people argue about whether their ostarine is better than their ligandrol, the measurable difference between the two compounds is roughly a kilogram of lean mass. The unmeasurable difference between what is in the bottle and what is printed on it is likely much larger.

Neither compound is in this shop’s catalogue, so the honest link is to where the two products actually are: Ostarine and Ligandrol. Those are catalogue entries, not results from the trials above.

What the data do not show

No trial compares ostarine against ligandrol in people. Any ranking of the two, in strength, in safety, in suppression or in value, is an extrapolation from two non-comparable studies plus opinion.

The pooled data do not show fat loss. Across 970 patients, pooled fat mass changed by a tenth of a kilogram in the other direction. If your expectation of a SARM is a fat-loss effect, the randomised literature does not contain it.

The trials do not show what happens over a year, or at the exposures people in the case reports actually used, or in anyone with a diagnosed condition, or in women taking anything at all, since both trials recruited a mixed group dominated by older men. They do not say anything about tendon, mood, or the cardiovascular markers that get discussed in forums and are not primary endpoints in any of these studies. And the case reports, which are the only source describing what happens at higher exposures in real people, cannot tell you a rate, because case reports are not built to.

For contrast, the class does have one compound with a real label and a real schedule: oxandrolone, approved in 1964 for weight regain and carrying liver warnings and Schedule III status ever since. Neither of the two above has any document like that.

The honest summary is narrow. Both compounds are nonsteroidal androgen receptor modulators with a published lean-mass signal in older or healthy volunteers over weeks to months, both carry documented hormonal and lipid suppression that reverses on stopping, and neither has an approved use. Everything past that point in this literature is either animal work, pooling, or case reports.